237 related articles for article (PubMed ID: 31779973)
1. How advanced are we in targeting novel subtypes of ALL?
Mullighan CG
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101095. PubMed ID: 31779973
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers in ALL: Clinical implications.
Kimura S; Mullighan CG
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101193. PubMed ID: 33038982
[TBL] [Abstract][Full Text] [Related]
3. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K; Sheikh T; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
[TBL] [Abstract][Full Text] [Related]
4. Biologic and Therapeutic Implications of Genomic Alterations in Acute Lymphoblastic Leukemia.
Iacobucci I; Kimura S; Mullighan CG
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501239
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.
Li JF; Dai YT; Lilljebjörn H; Shen SH; Cui BW; Bai L; Liu YF; Qian MX; Kubota Y; Kiyoi H; Matsumura I; Miyazaki Y; Olsson L; Tan AM; Ariffin H; Chen J; Takita J; Yasuda T; Mano H; Johansson B; Yang JJ; Yeoh AE; Hayakawa F; Chen Z; Pui CH; Fioretos T; Chen SJ; Huang JY
Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11711-E11720. PubMed ID: 30487223
[TBL] [Abstract][Full Text] [Related]
6. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
Paietta E; Roberts KG; Wang V; Gu Z; Buck GAN; Pei D; Cheng C; Levine RL; Abdel-Wahab O; Cheng Z; Wu G; Qu C; Shi L; Pounds S; Willman CL; Harvey R; Racevskis J; Barinka J; Zhang Y; Dewald GW; Ketterling RP; Alejos D; Lazarus HM; Luger SM; Foroni L; Patel B; Fielding AK; Melnick A; Marks DI; Moorman AV; Wiernik PH; Rowe JM; Tallman MS; Goldstone AH; Mullighan CG; Litzow MR
Blood; 2021 Sep; 138(11):948-958. PubMed ID: 33895809
[TBL] [Abstract][Full Text] [Related]
7. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.
Zaliova M; Stuchly J; Winkowska L; Musilova A; Fiser K; Slamova M; Starkova J; Vaskova M; Hrusak O; Sramkova L; Stary J; Zuna J; Trka J
Haematologica; 2019 Jul; 104(7):1396-1406. PubMed ID: 30630978
[TBL] [Abstract][Full Text] [Related]
8. Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.
Li J; Dai Y; Wu L; Zhang M; Ouyang W; Huang J; Chen S
Front Med; 2021 Jun; 15(3):347-371. PubMed ID: 33400146
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
[TBL] [Abstract][Full Text] [Related]
10. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial.
Schwab C; Cranston RE; Ryan SL; Butler E; Winterman E; Hawking Z; Bashton M; Enshaei A; Russell LJ; Kingsbury Z; Peden JF; Barretta E; Murray J; Gibson J; Hinchliffe AC; Bain R; Vora A; Bentley DR; Ross MT; Moorman AV; Harrison CJ
Leukemia; 2023 Mar; 37(3):529-538. PubMed ID: 36550215
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
[TBL] [Abstract][Full Text] [Related]
12. New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia.
Lilljebjörn H; Fioretos T
Blood; 2017 Sep; 130(12):1395-1401. PubMed ID: 28778863
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic Leukemia in an Academic Clinical Laboratory.
Hu Z; Kovach AE; Yellapantula V; Ostrow D; Doan A; Ji J; Schmidt RJ; Gu Z; Bhojwani D; Raca G
J Mol Diagn; 2024 Jan; 26(1):49-60. PubMed ID: 37981088
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
15. ETV6/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype.
Zaliova M; Kotrova M; Bresolin S; Stuchly J; Stary J; Hrusak O; Te Kronnie G; Trka J; Zuna J; Vaskova M
Genes Chromosomes Cancer; 2017 Aug; 56(8):608-616. PubMed ID: 28395118
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.
Krentz S; Hof J; Mendioroz A; Vaggopoulou R; Dörge P; Lottaz C; Engelmann JC; Groeneveld TW; Körner G; Seeger K; Hagemeier C; Henze G; Eckert C; von Stackelberg A; Kirschner-Schwabe R
Leukemia; 2013 Feb; 27(2):295-304. PubMed ID: 22699455
[TBL] [Abstract][Full Text] [Related]
17. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
19. Preserved global histone H4 acetylation linked to ETV6-RUNX1 fusion and PAX5 deletions is associated with favorable outcome in pediatric B-cell progenitor acute lymphoblastic leukemia.
Janczar K; Janczar S; Pastorczak A; Mycko K; Paige AJ; Zalewska-Szewczyk B; Wagrowska-Danilewicz M; Danilewicz M; Mlynarski W
Leuk Res; 2015 Dec; 39(12):1455-61. PubMed ID: 26520622
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
